FlandersBio on Twitter

Follow us on Twitter

Archive for May 2012 - News

Archive for May 2012 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Applied Maths appoints new Sales Director

30.05.2012

Applied Maths has strengthened its sales team with the appointment of Koen De Roo as Director of Sales. read more

Ono and Galapagos subsidiary BioFocus sign an additional target discovery agreement in the field of allergic disease

30.05.2012

Galapagos NV (Euronext: GLPG) and Ono Pharmaceutical Co., Ltd. (TSE: 4528) announced today that they have signed an additional collaboration agreement focused on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma. In the new agreement, Galapagos' service division BioFocus will use its SilenceSelect® platform to deliver validated targets to Ono. Ono aims to find modulators for these targets and generate novel drug candidates. Financial details were undisclosed. read more

Ajit Shetty strengthens reMYND’s Board of Directors

25.05.2012

reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director. read more

PharmaNeuroBoost Expands Further Product Portfolio with PNB03 and recruits First 250 Patients in the PNB01 Phase III Program

25.05.2012

The US Patent Office is willing to grant PharmaNeuroBoost (PNB) a patent for its third product being developed from her Boosting Technology Platform: PNB03. The FDA has approved the Phase III study for PNB’s firs product PNB01, for treatment of Major Depression. Already 250 out of 555 patients are being treated in the 32 American and Canadian centers participating in the study. read more

Kattenaids: er is iets aan te doen!

25.05.2012

Kattenaids (FIV) tast, net zoals HIV bij de mens, het immuunsysteem aan. Daardoor wordt een besmette kat vatbaar voor allerlei infecties die uiteindelijk dodelijk kunnen zijn. Tot nog toe was er geen behandeling voor de ziekte, maar daar komt nu verandering in. read more

Biocartis collaborates with Philips and Wellcome Trust in oncology diagnostics

25.05.2012

Biocartis announces that its researchers, in collaboration with researchers at the Wellcome Trust Sanger Institute and at Philips Research, are developing a novel workflow for extraction and amplification & detection of tumor DNA on Biocartis diagnostic platforms. Biocartis retains its full IP rights, with access to IP created during the scope of this collaboration. read more

Thrombogenics increases share capital through warrant exercises

25.05.2012

ThromboGenics NV (NYSE Euronext: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announced today a capital increase arising from employee warrant exercises. read more

Dr Patrik De Haes to be presented as the new chairman of FlandersBio at Knowledge for Growth

23.05.2012

Patrik De Haes has been appointed as the new chairman of the Board of Directors of FlandersBio. He succeeds Johan Cardoen who stands down after five years in the post. Patrik De Haes, who is the CEO of ThromboGenics, has been a director of FlandersBio for the last two years. read more

MDxHealth’s ConfirmMDxTM for Prostate Cancer Test Helps to Identify Men Able to Avoid Repeat Biopsies

23.05.2012

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx™ for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy. read more

Cryo-Save Group N.V. - Appointment of Ms. Karin Dorrepaal as Non-Executive Director

22.05.2012

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, is happy to welcome Ms. Karin Dorrepaal, PhD, MBA as its new Non-Executive Director. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print